TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback

Get the Brief in your inbox

A daily, SEC-grounded read on the market — movers, earnings, and our boldest calls. Free.

TTENK/calls

SEC-grounded equity research — opinionated calls reasoned over real filings.

Research

  • The Brief
  • Markets
  • All Stocks
  • Screener
  • Discover
  • Research
  • The Flip Side
  • Track record

Tools

  • Compare
  • Congress trades
  • Events
  • Filing search
  • Options calculator
  • Leaderboards
  • Insider trades
  • 13F funds
  • Groups
  • Trending
  • News

More

  • Pricing
  • Feedback
  • Newsletter
  • Developers / API
  • Account
DisclosuresTermsPrivacy

Research & education only — not financial advice.TENK is not a registered investment adviser; calls are impersonal, generated from SEC filings and a delayed/third-party price feed, and may be wrong or out of date. The operator and an affiliated trading operation may hold or trade the securities TENK rates — see Disclosures. Do your own research.

EDGAR® is a registered trademark of the U.S. Securities and Exchange Commission. TENK/calls is an independent service and is not affiliated with, endorsed by, or approved by the U.S. Securities and Exchange Commission.

TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback

Pulling SEC filings + quote and writing the call…

TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback
Home›PASG›Financials
Annual statements · SEC XBRL · FY2019 – FY2025

Passage BIO, Inc. (PASG) financials

Income statement

Passage BIO, Inc. (PASG) income statement, annual, from SEC filings
Fiscal yearFY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating income-$37.2M-$113M-$186M-$138M-$108M-$70.4M-$49.3M
Net income-$45.6M-$112M-$185M-$136M-$102M-$64.8M-$45.5M
EPS (diluted)-$10.77-$2.91-$3.48-$2.50-$1.86-$21.04-$14.35

Cash flow

Passage BIO, Inc. (PASG) cash flow, annual, from SEC filings
Fiscal yearFY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow-$39.9M-$80.5M-$127M-$118M-$78.3M-$48.0M-$31.5M
Capital expenditures—————$34.0K—
Free cash flow—————-$48.0M—

Balance sheet

Passage BIO, Inc. (PASG) balance sheet, annual, from SEC filings
Fiscal yearFY2019FY2020FY2021FY2022FY2023FY2024FY2025
Cash & equivalents$159M$135M$129M$34.6M$21.7M$37.6M$46.3M
Total assets$179M$328M$355M$244M$151M$102M$62.3M
Total liabilities$4.26M$23.3M$36.4M$42.2M$39.3M$41.2M$43.5M
Shareholders' equity-$56.3M$305M$319M$201M$111M$61.3M$18.8M
Retained earnings-$58.7M-$171M-$356M-$492M-$594M-$659M-$705M
Shares (wtd avg diluted)4.29M38.6M53.3M54.4M54.7M3.08M3.17M

Every figure is extracted from Passage BIO, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.

Common questions

Does PASG pay a dividend?
Passage BIO, Inc. reported no cash dividends paid in FY2025, per its SEC cash-flow statement.
Full PASG analysis — verdict, score & filings →Is PASG a buy? →

Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.